IRVINE, Calif., June 1 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP), today announced that it is scheduled to present at the Noble Financial Sixth Annual Equity Conference - ONTRACK 2010 to be held at the Hard Rock Hotel in Hollywood, Florida. Executive Chairman Paul J. McCormick will present a 30-minute corporate overview on Monday June 7, 2010 at 5:00 pm Eastern Time (2:00 pm Pacific Time) and meet one-on-one with investors during the conference. The presentation will be available through a live video webcast at www.cardiogenesis.com; click on investors. The webcast will also be available at www.ontrack10.com or www.nobleresearch.com.
About Cardiogenesis Corporation
Cardiogenesis is a medical device company specializing in the therapies for the treatment of chronic cardiac ischemia. The company's market leading Holmium:YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease. For more information on the company and its products, please visit the Cardiogenesis website at http://www.cardiogenesis.com.
SOURCE Cardiogenesis Corporation
Advertisement
About Cardiogenesis Corporation
Cardiogenesis is a medical device company specializing in the therapies for the treatment of chronic cardiac ischemia. The company's market leading Holmium:YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease. For more information on the company and its products, please visit the Cardiogenesis website at http://www.cardiogenesis.com.
SOURCE Cardiogenesis Corporation
